Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 10/20 | 0.59 |
| ▸ | PGR | P06401 | 3/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1136686 | 0.88 | NR3C1 (0.58) | NR3C1PGRARESR1SMN1; SMN2 | |
| SCHEMBL14274830 | 0.81 | NR3C1 (0.46) | NR3C1SMN1; SMN2KMT2ALMNAMAPK1 | |
| SCHEMBL12253757 | 0.80 | NR3C1 (0.58) | NR3C1PGRARESR1MEN1 | |
| SCHEMBL12864140 | 0.79 | NR3C1 (0.54) | NR3C1PGRARESR1SMN1; SMN2 | |
| SCHEMBL14197043 | 0.77 | NR3C1 (0.41) | NR3C1PGRARESR1SMN1; SMN2 | |
| SCHEMBL12862717 | 0.77 | NR3C1 (0.56) | NR3C1PGRARESR1SMN1; SMN2 | |
| SCHEMBL12862588 | 0.77 | NR3C1 (0.56) | NR3C1PGRARESR1SMN1; SMN2 | |
| SCHEMBL12305057 | 0.76 | NR3C1 (0.47) | NR3C1MEN1KMT2ACYP2C19GAA | |
| SCHEMBL14196981 | 0.74 | NR3C1 (0.57) | NR3C1PGRARESR1MEN1 | |
| SCHEMBL14274809 | 0.74 | NR3C1 (0.43) | NR3C1SMN1; SMN2MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896434-B1 | SUBSTITUTED HETEROARYL AMIDE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NFkB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2011-02-23 | — | — | EP | disclosed |
| EP-1575502-B1 | COMPOSITIONS AND METHODS INVOLVING NUCLEAR HORMONE RECEPTOR SITE II | BRISTOL MYERS SQUIBB CO (US) | 2010-01-20 | — | — | EP | disclosed |
| US-7442554-B2 | Compositions and methods involving glucocorticoid receptor site II | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442554-B2 | Compositions and methods involving glucocorticoid receptor site II | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-28 | — | — | US | disclosed |
| US-7411071-B2 | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-7411071-B2 | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-7361654-B2 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361654-B2 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361654-B2 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1896434-A1 | SUBSTITUTED HETEROARYL AMIDE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NFkB ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Pharma Company (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006076632-A1 | SUBSTITUTED HETEROARYL AMIDE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NFκB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060154973-A1 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154973-A1 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | NFRKB, NFKB2, NFKB1 | NR3C1 4/4885PGR 1658/4885AR 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.